https://www.journal-cot.com/article/S0976-5662%2816%2930248-X/fulltext#
Full length article| Volume 8, ISSUE 3, P209-214, July 2017
https://www.journal-cot.com/article/S0976-5662%2816%2930248-X/fulltext#
Full length article| Volume 8, ISSUE 3, P209-214, July 2017
Archives of Osteoporosis volume 17, Article number: 107 (2022) Cite this article
1326 Accesses; 1 Citations: 1 Altmetric
Hip fractures are the most common fractures requiring surgical treatment among adults. The highest incidences of hip fractures around the world have been observed in Northern Europe and the USA [1]. The age-standardized incidence of hip fractures in women is roughly twice as high as that in men, with some variability across the world [1]. In recent decades, the age-adjusted incidence of hip fractures has continuously decreased in high-incidence countries [2, 3]. According to a recent report from the four-decade Framingham Heart Study with 10,552 participants, the main reason for the observed decrease in hip fractures was a reduction in smoking and heavy drinking, which were important risk factors for fractures [4]. However, due to the increased number of hip fractures in developing countries [1], the worldwide overall annual number of hip fractures is still rising. It has been estimated that, by the year 2050, a staggering 6.3 million hip fractures worldwide will occur annually [5].
Several studies have reported that mortality among elderly hip fracture patients is higher than that of the age-adjusted general population and also higher among males than females [6, 7]. The mortality is increased during the first postoperative year, and it remains high for the following years [8]. Hip fractures are associated with increased short-term and long-term mortality. The post-hip-fracture mortality is 7–8% at 30 days [9, 10], 16–24% at 1 year [11, 12], 32–56% at 5 years [13, 14], and 80% at 10 years [15]. Reports evaluating survival beyond 10 years are scarce [16, 17].
The reasons for the increased mortality and morbidity in low-energy hip fracture patients entail several pre-fracture conditions: older age, male sex, pre-fracture comorbidities, poor preoperative walking capacity and activities of daily living, fracture type, low body mass index (BMI), high ASA class, and non-multidisciplinary postoperative rehabilitation [8, 10, 11, 18]. Alcohol consumption is associated with higher hip fracture risk and postoperative complications [4, 15].
The aim of this study was to identify patient-specific factors affecting postoperative short- and long-term survival, to study the survival in relation to the mortality in the reference population, and to analyze the mortality of the patients over a period of 14 years.
Methods:
The study was approved by the local ethics committee. We retrospectively analyzed all patients with a hip fracture (n = 506) requiring operative treatment at Päijät-Häme Central Hospital in Southern Finland (61° N) from January 1, 2005, to December 6, 2006 (Supplementary Fig. 1). The exclusion criteria were a pathological fracture, age under 18 years, non-operative treatment, and an undefined time of the fracture (Supplementary Fig. 1). The data were collected from electronic medical records.
All hip fracture patients had a low-energy fracture as a result of slipping, tripping, or falling from standing height or lower, as documented in the medical records. Fractures caused by high-energy injuries were excluded.
A low-energy hip fracture was identified as one of the following diagnosis codes: femoral neck fractures (S72.0), pertrochanteric fractures (S72.1), or subtrochanteric fractures (S72.2). Adult patients with new low-energy hip fractures who underwent one of the following procedures were analyzed: NFB10 (uncemented hemiarthroplasty); NFB20 (cemented hemiarthroplasty); NFJ50 (osteosynthesis of the neck with cannulated screws); NFJ52 (osteosynthesis of the proximal femur with a DHS or Medoff plate); NFJ54 (osteosynthesis with an intramedullary nail); NFJ64 (osteosynthesis with additional screws or wires); NFB30 (uncemented primary total hip arthroplasty); NFB40 (hybrid total arthroplasty); or NFB50 (cemented primary total hip arthroplasty). The surgical procedure codes were collected according to the Nordic Medico-Statistical Committee’s classification of surgical procedures (NOMESCO). The medical records of all patients were checked manually (R.T.).
The baseline characteristics of patients are shown in Table 1. Patient-specific variables included the patient’s personal ID number, sex, age, date of injury, American Society of Anesthesiologists (ASA) class [19], body mass index (BMI; kg/m2), selected comorbidities, fracture type, date of operation, type of operation and implant, date of discharge, and death. BMI was divided into four groups: < 20, 20–24.9, 25–29.9, and > 30 kg/m2. Pre-existing selected comorbidities increasing the risk of falling were identified from the medical records individually (alcohol involvement [AI], Alzheimer’s disease, dementia, stroke, Parkinson’s disease, previous intracranial hemorrhages [ICH], transient ischemic attack [TIA], and severe psychiatric diseases with ongoing medication [e.g., schizophrenia]).
..Fracture classification
The type of hip fracture was analyzed from the preoperative radiographs by the study group (RT, JPK). The fractures were classified as femoral neck fractures (S72.0), pertrochanteric fractures (S72.1), and subtrochanteric fractures (S72.2). Femoral neck fractures were further classified according to the Garden classification [20]. The type of trochanteric (S72.1) and subtrochanteric (S72.2) hip fractures was graded according to the AO classification [21]. We also evaluated the number of basicervical hip fractures [22]. Basicervical fractures were classified as pertrochanteric fractures (S72.1). One radiograph in group S72.1 and 8 radiographs in group S72.2 were missing for AO classification (Supplementary Table 1).
--
In a Swedish retrospective registry-based cohort study (n = 1493) regarding 1-year mortality, results similar to our present study were found [10]. Mortality was significantly associated with age, male sex, and ASA class 3–5, but the type of fracture or operation method did not affect the mortality estimates [10]. Different results have also been reported. A recent Finnish prospective study on home-dwelling hip fracture patients (n = 538) showed no sex-related differences in mortality at 4 and 12 months postoperatively [27]. Furthermore, one opposite result had been published—in an earlier prospective study (n = 106) from Finland, the 1-year mortality was higher in women than in men (34% vs 28%), although the difference was not significant [28].
Furthermore, a Norwegian study (n = 942, mean age 81.2 years) reported that the elevated mortality at 1 year and 5 years postoperatively was significantly associated with male sex and age over 80 years [7]. The overall mortality after the first year was 21% and after 5 years 59% [7]. In the present study (mean age 79 (SD 12.1 years), the corresponding results were similar, 22% and 57%, respectively.
A Danish national register study [17] showed that the postoperative mortality after hip fractures varied between 2000 and 2013 but did not decline. The mortality rate was 10% at 30 days, 16% at 90 days, and 27% at 1 year [17]. In Denmark, the median length of the postoperative acute hospital stay in 2014 (8 days) [17] was similar to that of our study (9 days).
Purpose: Hip fractures are one of the most common disabling fractures in elderly people and peri-operative management has advanced considerably over the past decades. The purpose of this study was to evaluate the change of scientific focus by creating a top 50 list of the most influential papers on this topic.
Hip fractures are one of the most common fractures in elderly patients [1]. The one year mortality ranges between 14 and 36% [2, 3]. In 2000, more than 1.6 million hip fractures occurred globally and accounted for 20% of all fractures in patients over 50 years [4]. It is estimated that the absolute number of annual fractures will be 4.5 million by the year 2050 [5, 6]. Hip fractures are among the classic fragility fractures of geriatric patients and more than 90% are caused by low energy trauma (i.e. fall from standing height). Established risk factors are osteoporosis, high age, female sex, smoking and a low BMI [4, 7,8,9]. They can be classified into femoral neck fractures, per- or intertrochanteric fractures and subtrochanteric fractures [10]. While per- or intertrochanteric fractures are treated with osteosynthesis devices, femoral neck fractures can be either treated with hemi- and total hip arthroplasty or osteosynthesis [11].
The enormous prevalence of hip fractures accentuates the socio-economic significance and explains the sheer infinite number of published articles [12]. In an era of evidence-based medicine, research studies are not only important for a better understanding but also in clinical decision-making. With the increase in studies published recently, it is becoming difficult to overlook the most current research questions. One way to determine the impact of a published article is to use the citation analysis [13,14,15,16,17,18]. Although the quality of an article does not depend solely on its citation rate, it represents its importance in the field and is widely recognized in the scientific community.
The aim of this study was to identify the top 50 most influential articles on hip fractures. To characterize the change of scientific focus and research questions in recent years, the top ten articles over the last five years (2015–2020) were separately evaluated. It was hypothesized that the literature on hip fracture treatment would change over the decades, as the evidence base and quality of studies were expected to improve over time.
From: The top fifty most influential articles on hip fractures
From: The top fifty most influential articles on hip fractures
No | Article name | No. of citations (citation density) | Topic | Study design | Evidence level |
---|---|---|---|---|---|
1 | Pincus D, Ravi B, Wasserstein D, Huang A, Paterson JM, Nathens AB, et al. Association Between Wait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery. JAMA. 2017;318:1994–2003 | 74 (18.5) | Risk factor assessment | Retrospective cohort study | III |
2 | Rogmark C, Leonardsson O. Hip arthroplasty for the treatment of displaced fractures of the femoral neck in elderly patients. Bone Joint J. 2016;98-B:291–7 | 52 (10.4) | Surgical treatment | Review | IV |
3 | Nauth A, Creek AT, Zellar A, Lawendy A-R, Dowrick A, Gupta A, et al. Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial. The Lancet. 2017;389:1519–27 | 39 (9.8) | Surgical treatment | Randomized controlled trial | II |
4 | Sheikh HQ, Hossain FS, Aqil A, Akinbamijo B, Mushtaq V, Kapoor H. A Comprehensive Analysis of the Causes and Predictors of 30-Day Mortality Following Hip Fracture Surgery. Clin Orthop Surg. 2017;9:10–8 | 30 (7.5) | Risk factor assessment | Retrospective case series | IV |
5 | Socci AR, Casemyr NE, Leslie MP, Baumgaertner MR. Implant options for the treatment of intertrochanteric fractures of the hip: rationale, evidence, and recommendations. Bone Joint J. 2017;99-B:128–33 | 30 (7.5) | Surgical treatment | Review | V |
6 | Kilci O, Un C, Sacan O, Gamli M, Baskan S, Baydar M, et al. Postoperative Mortality after Hip Fracture Surgery: A 3 Years Follow Up. PLoS One. 2016;11:e0162097 | 28 (5.6) | Risk factor assessment | Retrospective case series | IV |
7 | Forni S, Pieralli F, Sergi A, Lorini C, Bonaccorsi G, Vannucci A. Mortality after hip fracture in the elderly: The role of a multidisciplinary approach and time to surgery in a retrospective observational study on 23,973 patients. Arch Gerontol Geriatr. 2016;66:13–7 | 28 (5.6) | Additional treatment | Retrospective cohort study | IV |
8 | Folbert EC, Hegeman JH, Vermeer M, Regtuijt EM, van der Velde D, Ten Duis HJ, et al. Improved 1-year mortality in elderly patients with a hip fracture following integrated orthogeriatric treatment. Osteoporos Int. 2017;28:269–77 | 27 (6.8) | Additional treatment | Prospective cohort study | II |
9 | Bohl DD, Shen MR, Hannon CP, Fillingham YA, Darrith B, Della Valle CJ. Serum Albumin Predicts Survival and Postoperative Course Following Surgery for Geriatric Hip Fracture. J Bone Joint Surg Am. 2017;99:2110–8 | 26 (6.5) | Risk factor assessment | Retrospective cohort study | IV |
10 | Farrow LS, Smith TO, Ashcroft GP, Myint PK. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol. 2016;82:1458–70 | 26 (5.2) | Hemodynamic management | Systematic review and meta-analysis | II |
https://pubmed.ncbi.nlm.nih.gov/30426086/
Background: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft.
Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void.
Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results.
Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.
Keywords: Bone defect; Bone substitute; Bone tumor.
Artikkelissa kuvataan tavallista lapsille sattuvaa traumaa, lapsen sääri-ja ohjeluun samanaikaismurtumaa. useimmiten hoito on konservatiivista, reduktio ja kipsi , muta joskus joudutaan kirurgiseen hoitoon, levyn asennus, Kirschnerin langat ja luuytimen vahvistus metallipiikillä). Tässä kuvauksessa kerrotaan poikkeuksellisesta havainnosta: murtumakohdassa näkyi epätavallinen vaurio.. luutonta fibroma-aluetta, joka kirurgisesti poistettiin ja luuvajekohtaan asetettiin luutakorvaavaa materiaa, CERAMENT- nimistä luupuutekohdan täyteainetta, jossa on kalsiumsulfaattia 60 % ja 40% hydroksiapatiittia. (Ps. Tämä luuaukkokohtaan ruiskutettava ja vain hetken ajan voidemaisena ja ruiskutetavissa oleva aine valmistetaan pulverin ja veden seoksesta aivan juuri käyttöhetkellä operaation kuluessa. Kyse on todellakin sekunneista, sillä siinä tapahtuu kuumeneminen ja kuivuminen, jolloin se ei enää ole ruiskutettavissa kohdepisteeseensä. Tämä vaatii asiaan koulutettua leikkaussalihoitajaa tietysti. Aines ajan mittaan katoaa samalla kun uutta luuta muodostuu).
https://pubmed.ncbi.nlm.nih.gov/36381795/
eCollection 2022 Oct.
Paediatric distal tibial and fibular fractures are seen quite regularly in orthopaedic trauma practice. Most patients are managed conservatively with closed reduction or casting while only a selected few required surgical treatment. Surgical options include plating, percutaneous Kirschner wires, rigid intramedullary nails, and flexible intramedullary nailing. This is dependent upon the patient's age, fracture site, comminution, and concomitant injuries. Here, we present an interesting case of a patient with an unusual lesion seen at the fracture site. This lesion was curetted out during surgery and filled with an injectable synthetic Cerament bone void filler (Bone Support AB, Lund, Sweden), which later formed into bone and allowed the bone to remodel.
Keywords: bone grafts; bone lesion; distal fibula; distal tibia fracture; non-ossifying fibroma; open reduction internal fixation; orthopaedics surgery; orthopaedics trauma; paediatrics orthopaedics; synthetic bone graft.
Copyright © 2022, Siddiqui et al.
First published: 24 October 2020
https://doi.org/10.1002/jor.24896
Chronic osteomyelitis has always been a therapeutic challenge for patient and surgeon due to the specific problems related with bone infection and bacterial biofilm eradication. Other than being the cause of infection or facilitating spread or persistence of infection, biomaterials are also becoming a tool in the treatment of infection.
Certain novel biomaterials have unique and ideal properties that render them perfectly suited to combat infection and are therefore used more and more in the treatment of chronic bone infections.
In case of infection treatment, there is still debate whether these properties should be focused on bone regeneration and/or their antimicrobial properties.
These properties will be of even greater importance with the challenge of emerging antimicrobial resistance.
This review highlights indications for use and specific material properties of some commonly used contemporary biomaterials for this indication as well as clinical experience and a literature overview.
In orthopedic surgery and traumatology, bone infection is an underestimated and challenging condition for both the patient and the physician. Diagnosis can be difficult,1 treatment is often prolonged and cumbersome, sometimes involving multiple surgeries and can impose a significant financial burden on both the patient and the health system in general. Although tremendous progress has been made in the treatment of musculoskeletal infection over the years, studies have shown that elective surgery infection rates are not able to be reduced below 1–2% and failures of revision surgery remain as high as 33%.2, 3 The cost of treating bone infection is substantial and will increase as the absolute number of patients suffering from it keeps rising.4
Two specific entities of orthopedic infection can be identified: those infections that only involve bone (osteitis/osteomyelitis) and those affecting bone and an associated implant, like a joint replacement or some kind of osteosynthesis. Both entities are different in their approach, although overlap exists. To improve treatment outcomes, biomaterials have been used to help eradicate infection, fill bony defects and support remaining bone and/or implants. Some biomaterials function as antibiotic-delivery devices, such as gentamicin-loaded beads or spacers, as developed by Wahlig and Dingeldein in the 70s.5 Locally, they release high doses of antibiotics, far higher than the minimal inhibitory concentration (MIC) and higher than what can be achieved by parenteral administration of the same antibiotic, thereby eradicating an important part of the local bacterial load. These antibiotic-loaded bone cements have served well over time, although several concerns have been addressed like antibiotic elution levels becoming subtherapeutic, thereby possibly inducing antimicrobial resistance, the absence of standardized formulation protocols and the absence of validated assays to determine the minimum biofilm eradication concentration to predict efficacy of these antibiotic-loaded bone cements against specific microorganisms.6
Other materials have also been shown to have antibacterial properties and are used to coat the surface of an implant like nanoparticles, such as silver (Ag), magnesium (Mg), copper (Cu), and gold (Au) to prevent infection (by inhibiting the surface to be colonized by bacteria, who would than outrun host-cells in the race for the surface).7-9 This is the concept, first described by Gristina in 1987, whereby when any foreign material is introduced in the body, a “race” will occur between our own cells/immune system and the microorganisms.10, 11 If the implant is covered by human or eukaryotic cells first, it will be “shielded” and as such be more difficult to reach for microorganisms. Eventually, (osseo)integration of the implant in the surrounding tissues will occur. On the other hand, if microorganisms are first, the implant will be contaminated. As soon as bacteria or other microorganisms bond with the surface, they will form biofilm, rendering themselves much more resistant to the body's immune system. This is because our immune cells cannot easily penetrate this biofilm and because bacteria downregulate their metabolism so they do not duplicate as often (metabolically less active), compared to their planktonic (or free-floating) counterparts. The latter is also the reason why antibiotics are less effective for bacteria in biofilm, with MICs that can be 1000-fold higher.12, 13 So, in essence bacteriae cover themselves in a slime layer when adhering on an implant, but when looking closer, biofilm is much more complex and concepts like metabolism, growth rate, gene expression changes, or persistor cells have to be taken into account.
Coating technology and implant modification (for instance: biomaterials with empirical antimicrobial behavior) to combat biofilm formation and/or persistence still deal with several concerns and necessitate further research, but will become important future methods to deal with implant-related infection.14 Because of this, a separate working group was established at the 2018 International Consensus Meeting on Musculoskeletal Infection to provide insights on the biomaterial surface question.15
..
There are multiple commercially available biodegradable biomaterials that are studied for treatment of chronic osteomyelitis in a one-stage fashion (Table 1).
These materials are generally based on antibiotic loaded calcium sulfates, calcium phosphates, or bioactive glasses.
Product name | Composition | Antimicrobial mechanism | Antibiotic type | Level of evidencea |
---|---|---|---|---|
BonAlive® | S53P4 bioactive glass S53P4 (53% SiO2, 4% P2O5, 23% Na2O, and 20% CaO) | Release of surface ions causing increase of pH and osmotic pressure | None | 2b |
Cerament G/V® | 60% calcium sulfate, 40% hydroxyapatite | Antibiotic loaded BGS | Gentamicin, vancomycin | 2b |
Herafill-G® | Calcium sulfate and calcium carbonate | Antibiotic loaded BGS | Gentamicin | 3b |
Osteoset-T® | ɑ-Hemihydrate calcium sulfate | Antibiotic loaded BGS | Tobramycin | 2b |
Perossal® | Nano-crystalline hydroxyapatite (51.5%) and calcium sulfate (48.5%) | Antibiotic loaded BGS | Different types of antibiotics (surgeon's choice) | 2b |
Stimulan® | Hemihydrate calcium sulfate | Antibiotic loaded BGS | Gentamicin, vancomycin, tobramycin | 2b |